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A Phase II Study of Dasatinib in Patients with
Chemosensitive Relapsed Small Cell Lung Cancer
(Cancer and Leukemia Group B 30602)
Antonius A. Miller, MD,* Herbert Pang, PhD,† Lydia Hodgson, MS,† Nithya Ramnath, MD,‡
Gregory A. Otterson, MD,§ Michael J. Kelley, MD,† Robert A. Kratzke, MD,
and Everett E. Vokes, MD,¶ for the Cancer and Leukemia Group B (CALGB)
Introduction: SRC is an oncogene with an essential role in the
invasiveness and metastasis of solid tumors including small cell lung
cancer. Dasatinib is a potent inhibitor of SRC as well as other
tyrosine kinases. The primary objective of this study was to deter-
mine the efficacy of second-line dasatinib in patients with chemo-
sensitive (relapse or progression90 days after completing first-line
therapy) small cell lung cancer.
Methods: Patients with measurable disease; performance status 0 to
1; no more than one prior platinum-based chemotherapy regimen;
and adequate hematologic, hepatic, and renal function were eligible.
Dasatinib was administered orally at 70 mg twice daily continuously
(1 cycle  21 days) until disease progression or unacceptable
toxicity. Response was determined after every two cycles. Patients
were followed until disease progression or death. The study was
prospectively designed to simultaneously discriminate between
complete plus partial response rates of 5% versus 20% and progres-
sion-free survival (PFS) rates at 6 weeks of 50% versus 70.7% in 53
evaluable patients with at least 92% power. The study was to be
terminated early and declared negative if 1 or less objective response
and 14 or fewer instances of PFS 6 weeks were observed among
the initial 27 patients; however, patient accrual continued while the
initial 27 patients were evaluated.
Results: Between April 2007 and December 2008, 45 patients were
enrolled, but one patient never received any protocol therapy and
one patient was ineligible: male/female, 17/26; white/black/un-
known, 40/2/1; median age, 64 years (range, 35–84 years); and
performance status 0/1, 12/31. No objective response was recorded
among the 43 eligible and treated patients. Among the initial 27
patients, only 13 instances of PFS 6 weeks were observed. With a
median follow-up time of 7.1 months, median estimated overall
survival and PFS times for the 43 eligible and treated patients were
17.0 and 5.9 weeks, respectively. Common reasons for removal of
patients from protocol treatment were progressive disease (65%) and
adverse events (26%). Toxicity was generally mild to moderate:
grade 3 events of 5% frequency included fatigue and pleural and
pericardial effusions; and no grade 4 or 5 events were encountered.
Conclusions: Dasatinib did not reach our specified efficacy criteria
in this clinical setting, and the study was terminated.
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Lung cancer remains the leading cause of cancer deaths inboth males and females in the United States.1 Small cell
lung cancer (SCLC) accounts for about 15% of all lung
cancer.2 Progress in conventional treatment of SCLC has
been slow in recent years.3 Despite often dramatic initial
responses to appropriate therapy, most patients with SCLC
relapse and die, resulting in an overall 5-year survival rate of
approximately 10%. Treatment with platinum-based chemo-
therapy plus thoracic radiotherapy has resulted in impressive
response rates of 80 to 90% in patients with potentially
curable limited-stage disease, but median survival is only
approximately 21 months and 5-year survival is approxi-
mately 20%. In patients with extensive-stage disease, plati-
num-based chemotherapy also yields high initial response
rates of 60 to 80%, but long-term survival is rare.
Salvage or second-line chemotherapy for SCLC has
been disappointing, and the only Food and Drug Administra-
tion-approved drug, topotecan, results in transient responses
in 6 to 37% of patients, depending upon the timing of
relapse.4,5 Patients with “refractory” disease (relapsing within
60–90 days of initial treatment) experience a worse response
rate compared with those with “sensitive” relapse (60–90
days from completion of initial therapy).4,5 One randomized
study supported the use of topotecan in the second-line
setting when compared with combination therapy with cyclo-
phosphamide, doxorubicin, and vincristine (CAV) in that
there was equivalent efficacy but less toxicity.6 Nonetheless,
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the time to progression in this study was 12 to 13 weeks.
Clearly, novel approaches are needed in this disease.
Dasatinib, an aminothiazole analogue, is an orally ad-
ministered inhibitor of protein tyrosine kinases that have been
linked to human malignancies, including BCR-ABL, c-KIT,
c-SRC, PDGF receptor, and EPHA2.7,8 It is more potent
than imatinib in inhibiting BCR-ABL and has been Food and
Drug Administration-approved for use in chronic myeloge-
nous leukemia and Philadelphia chromosome-positive acute
lymphoblastic leukemia after imatinib failure or intolerance.
c-KIT9–12 and c-SRC13–15 are expressed in SCLC. In cultured
SCLC cell lines, c-SRC expression was found to be corre-
lated with neuroendocrine differentiation of cells.14 In a
preclinical immunohistochemical analysis, c-SRC was ex-
pressed in 17 of 19 SCLC tumor tissues and considered a
promising molecular target for therapy.16 Blockade of c-SRC
kinase decreased basal and neuropeptide-induced survival
and proliferation of SCLC cells in liquid culture and semi-
solid medium.17 Inhibition of neuropeptide-stimulated ty-
rosine phosphorylation and tyrosine kinase activity also stim-
ulated apoptosis in SCLC cells.18 Whereas c-SRC protein
kinase activity was detected in SCLC cell lines and tissues,
normal lung had low levels of kinase activity.19
The primary objectives of this phase II study were to
determine (a) the efficacy of second-line dasatinib in chemo-
sensitive SCLC (patients with relapse or progression 90
days after completing first-line therapy) and (b) the progres-
sion-free survival (PFS) at 6 weeks of treatment. Secondary
objectives were to document the objective response rate,
progression-free and overall survival, and toxicity of dasat-
inib in this patient population.
PATIENTS AND METHODS
Patient Eligibility
All patients had pathologically documented SCLC and
had received no more than one prior chemotherapy regimen.
The disease had to have progressed or recurred after initial
response to first-line, platinum-based chemotherapy with or
without concurrent definitive radiation to the chest depending
on whether the patient initially presented with limited or
extensive stage. The first-line chemotherapy had to be com-
pleted 90 days before documentation of relapse. Prior
radiation therapy was allowed in the context of combined
modality treatment for limited stage disease, prophylactic
cranial radiation, or palliative radiation initially or at relapse,
but 2 weeks had to have elapsed since radiation. Patients
with brain metastases were eligible as long as the brain
metastases had been treated and patients were neurologically
stable for 4 weeks. Prior treatment with dasatinib or other
tyrosine kinase inhibitors was not permitted. Concurrent
treatment with any other chemotherapeutic or investigational
agent was not allowed. Measurable disease was required.
Other eligibility criteria included age 18 years and Eastern
Cooperative Oncology Group performance status 0 to 1.
Patients with significant cardiac disease (congestive heart
failure, prolonged QTc, and major conduction abnormality)
and HIV-positive patients on combination antiretroviral ther-
apy were ineligible. Female patients who were pregnant or
nursing were excluded. The required laboratory values at
entry were absolute neutrophil count  1500/L; platelet
count  100,000/L; total bilirubin  1.5  upper limit of
normal (ULN); serum glutamic oxaloacetic transaminase (as-
partate transaminase)  2.5  ULN; and serum creatinine
 1.5  ULN or creatinine clearance  60 mL/min. The
study had to be approved by the Institutional Review Board
of each participating institution. Each patient had to give
written informed consent.
Treatment Plan
Patients received dasatinib on an outpatient basis at a
dose of 70 mg by mouth twice daily. Three weeks constituted
one cycle of treatment. Treatment was continued daily until
disease progression or intolerable toxicity. Dasatinib tablets
were taken with or without food as desired and had to be
swallowed with at least 8 ounces (240 mL) of water. Pill
counts and medication calendars were used to monitor adher-
ence. To avoid interactions with other drugs and substances,
the protocol contained a detailed section that can be summa-
rized as follows. Drugs with proarrhythmic potential were not
permitted for 7 days before and during dasatinib treatment.
Likewise, potent inhibitors or inducers of cytochrome P450
enzyme CYP3A4 were prohibited. Patients were also not
allowed to consume grapefruit for 7 days before and during
dasatinib treatment. Patients who required antacids used
short-acting, locally active agents but not within 2 hours
before or 2 hours after the dasatinib dose.
Dasatinib (BMS-354825, NSC #732517, IND #73969)
was supplied for this study by the Division of Cancer Treat-
ment and Diagnosis of the National Cancer Institute (NCI).
Dasatinib was provided to the NCI under a Cooperative
Research and Development Agreement between Bristol My-
ers Squibb Pharmaceuticals Co., Ltd., and the Division of
Cancer Treatment and Diagnosis, NCI. Dasatinib was avail-
able in 20 and 50 mg tablet sizes.
The starting dose of dasatinib was 70 mg twice daily. A
maximum of two dose reductions to 50 mg twice daily and
100 mg once daily was specified in the protocol if toxicity
was encountered. Dasatinib was held for grade 3 and 4
neutropenia or thrombocytopenia and restarted at a lower
dose once toxicity had improved to grade 2. Dasatinib was
held for grade 2 hemorrhage, bleeding, or coagulopathy and
restarted once toxicity had improved to grade 1, but only
one dose reduction was allowed. Recurrent grade 2 and any
grade 3 or 4 hemorrhage, bleeding, or coagulopathy required
discontinuation of treatment. The electrocardiogram was as-
sessed for QTc prolongation, concomitant medications were
reviewed, and electrolyte abnormalities were corrected. For
QTc prolongation 550 milliseconds, dasatinib was stopped
and only restarted if QTc 480 milliseconds after 14 days.
For other nonhematologic toxicity of grade 3 or 4 severity,
dasatinib was held, supportive therapy was maximized, and
then a dose reduction instituted. Supportive care included
measures for nausea, vomiting, and diarrhea (such as granis-
etron and other antiemetics and loperamide for diarrhea) as
well as measures to reduce fluid retention and inflammation
(such as diuretics and steroids). Patients requiring radiation
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therapy during protocol treatment were considered to have
progressed and were removed from protocol treatment.
Clinical Evaluation
Before enrollment in the study and before each treat-
ment cycle (21 days), a comprehensive history and physical
examination were performed, and complete blood counts
with differential and serum chemistries were obtained. Blood
counts were obtained weekly during the first cycle. Staging
studies were performed before enrollment and after every two
cycles of therapy. The Response Evaluation Criteria in Solid
Tumors (RECIST) by the NCI were applied.20 The Common
Terminology Criteria for Adverse Events (Version 3.0) from
the NCI (http://ctep.cancer.gov) were used. After the protocol
therapy was completed, patients were followed at least every
3 months for 1 year and then every 6 months for 3 years or
until progression or death. Patient registration and data col-
lection were managed by the Cancer and Leukemia Group B
(CALGB) Statistical Center. Data quality was ensured by
careful review of data by CALGB Statistical Center staff and
by the study chairman. Statistical analyses were performed by
CALGB statisticians.
Statistical Analyses
Topotecan is the only drug approved by the Food and
Drug Administration of the United States for relapsed SCLC.
In the trial of topotecan versus CAV in patients with progres-
sive disease at least 60 days after completion of front-line
chemotherapy, the response rates were 24.3% for topotecan
and 18.3% for CAV.6 Median times to progression were 13.3
weeks for topotecan and 12.3 weeks for CAV. The current
study was prospectively designed to simultaneously discrim-
inate between complete plus partial response rates of 5%
versus 20% and PFS rates at 6 weeks of 50% versus 70.7% in
53 evaluable patients with at least 92% power. The study was
to be terminated early and declared negative if 1 or less
objective response and 14 or fewer instances of PFS 6
weeks were observed among the initial 27 patients. However,
patient accrual continued while the initial 27 patients were
evaluated because of the logistics of running this trial in a
large cooperative group. Kaplan-Meier curves were used to
describe PFS and overall survival.21 PFS was the time from
randomization until disease progression, death, or last known
follow-up. Survival was the time between randomization and
death of any cause.
As part of the quality assurance program of the
CALGB, members of the Audit Committee visit all partici-
pating institutions at least once every 3 years to review source
documents. The auditors verify compliance with federal reg-
ulations and protocol requirements, including those pertain-
ing to eligibility, treatment, adverse events, tumor response,
and outcome in a sample of protocols at each institution. Such
on-site review of medical records was performed for a sub-
group of 4 of the 45 patients in this study.
RESULTS
Patient Characteristics
Between July 2007 and December 2008, 45 patients
were enrolled. One patient never started treatment. One
patient was ineligible because of neutropenia. The median
age of the 43 eligible and treated patients was 64 years
(range, 35–84 years). All patients had received prior chemo-
therapy and 34 (79%) had received prior radiation therapy.
The other demographic and baseline clinical characteristics
are shown in Table 1.
Response
Table 2 shows the response to therapy. No complete or
partial responses were observed. The rate of stable disease
was 16%, and the median duration of stable disease was 12.3
weeks (95% confidence interval [CI], 6.3–33.9 weeks). The
reasons for inadequate assessments of response included
patient refusal to continue on protocol therapy and with-
drawal of consent (n  3), disease progression (n  3),
adverse event (chest pain and rash, n  1), and early death
(n  1). One patient withdrew consent without giving a
reason; one patient with bilateral pleural effusions who re-
TABLE 1. Patient Demographic and Initial Clinical
Characteristics (n  43)
Characteristic n (%)
Sex
Male 17 (40)
Female 26 (60)
Race
White 40 (93)
Black 2 (5)
Unknown 1 (2)
Ethnicity
Non-Hispanic 40 (93)
Hispanic 3 (7)
Performance status
0 12 (28)
1 31 (72)
Disease sites
Primary lung 31 (72)
Contralateral lung 4 (9)
Lymph nodes
Hilar 19 (44)
Mediastinal 24 (56)
Supraclavicular 8 (19)
Other 15 (35)
Pleura 6 (14)
Liver 21 (49)
Adrenals 9 (21)
Bone 9 (21)
Brain 3 (7)
Other 11 (26)
TABLE 2. Response to Therapy (n  43)
Response n (%)
Stable disease 7 (16)
Progressive disease 28 (65)
Inadequately assessed 8 (19)
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quired thoracenteses, which resulted in pneumothorax and
atrial fibrillation with rapid ventricular response, elected to be
removed from protocol treatment; and one patient withdrew
consent because of poor appetite and gastrointestinal symp-
toms that were more likely related to her malignant disease
process than the protocol therapy. The patient with the early
death was a 66-year-old woman (active smoker) with superior
vena cava syndrome from SCLC and with pulmonary, pleu-
ral, and peritoneal involvement, intrathoracic and intraab-
dominal lymph node metastases, and liver metastases who
was admitted to the hospital on day 8 of cycle #1 with
respiratory insufficiency attributed to her advanced SCLC
and exacerbation of chronic obstructive pulmonary disease;
she did not improve despite intensive therapy and decided for
comfort measures. The reasons for the discontinuation of
protocol treatment were progressive disease (n  28; 65%),
adverse events (n  11; 26%), withdrawal of consent (n  3;
7%), and early death (n  1; 2%).
Survival
Among the initial 27 patients, only 13 instances of PFS
6 weeks were observed. Among all 43 patients, the 6-week
PFS rate was 43% with a 95% CI of 30 to 61%. The median
follow-up time was 7.1 months, and 32 patients have died.
For all 43 patients, the PFS was 5.9 weeks (95% CI, 5.7–6.6
weeks) and the overall survival was 17.0 weeks (95% CI,
14.6–29.7 weeks).
Toxicity
The toxicity assessment included all 44 (43 eligible and
1 ineligible) patients who received the protocol treatment.
The grade 3 treatment-related adverse events are listed in
Table 3. The most common side effect as defined by the
Common Terminology Criteria for Adverse Events under
constitutional symptoms was fatigue (asthenia, lethargy, and
malaise). The pleural and pericardial effusions were consid-
ered by the treating physician to be related to treatment rather
than related to the malignant disease. The overall number of
patients with grade 3 adverse events was 12 (27%). No grade
4 or 5 adverse events were encountered.
DISCUSSION
As stated in the statistical section, the study was to be
terminated and declared negative if 1 or less objective re-
sponse and 14 or fewer instances of PFS 6 weeks were
observed among the initial 27 patients. These prospectively
set targets were both met. Hence, dasatinib did not reach our
specified efficacy criteria in this clinical setting, and the study
was terminated. A limitation of this study is that the expec-
tations for this biologic, noncytotoxic agent were arbitrarily
set and perhaps too high. The study protocol allowed contin-
uation of accrual after the initial 27 patients were entered. As
a result, 18 additional patients were enrolled although dasat-
inib was ultimately considered inactive. In the future, the trial
design should call for suspension of accrual after the initial
cohort of patients.
c-KIT9–12 and c-SRC13–15 are expressed in a variety of
neoplasms, including SCLC. A limitation of this study is that
tumor tissue of the patients was not assessed for the expres-
sion c-KIT or c-SRC. However, it does not seem that SCLC
responds clinically to the inhibition of these tyrosine kinases
by dasatinib. Single-agent therapy with tyrosine kinase inhib-
itors, such as dasatinib, may be ineffective in malignancies in
which proliferation is not dependent on tyrosine kinase ac-
tivity. It is also possible that activation mutations of tyrosine
kinases are required for antitumor efficacy. A more compre-
hensive preclinical evaluation of dasatinib, including in vivo
studies, should have been conducted before launching this
trial. In this regard, our experience is similar to a phase II
study of imatinib that also showed no activity in this dis-
ease.22 In that study, tumors that were c-KIT positive were
selected for the treatment with imatinib, but the presence of
the molecular target was not sufficient for clinical efficacy.
The redundancy of multiple aberrant growth and survival
pathways may make any single therapeutic intervention un-
likely to be successful in SCLC. Although progress has been
made in non-small cell lung cancer with the tyrosine kinase
inhibitor erlotinib and other drugs, therapeutic advances in
SCLC have been sparse in over 2 decades.3
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